ArticleFrontiers in oncology2026
Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hormone receptor-positive (HR+) endometrial carcinoma (EC) responds to endocrine therapy, but clinical benefit duration is often limited, especially in patients with widely metastatic or recurrent disease. Case: A 54-year-old woman with HR-high (ER/PR 90%) metastatic EC (FIGO IIIC2) discontinued adjuvant chemotherapy due to severe toxicity. She initiated megestrol acetate and letrozole in March 2017, achieving stable disease (SD) for 38 months. Self-discontinuation (January-July 2020) led to disease progression (new retroperitoneal lymph nodes), but resuming full-dose therapy restored SD for 49 months. After dose reduction (July 2023), the disease progressed again at 12 months; re-escalation to full dose induced regression. At last follow-up (OS: 108 months), she maintained SD with minimal toxicity. Conclusion: This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.